Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Apr;62(4):1427–1436. doi: 10.1128/iai.62.4.1427-1436.1994

Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats.

A W Cripps 1, M L Dunkley 1, R L Clancy 1
PMCID: PMC186298  PMID: 8132349

Abstract

The aim of this study was to determine the efficacies of prior mucosal (oral, intra-Peyer's patch, or intratracheal) and systemic (subcutaneous) immunizations with killed Pseudomonas aeruginosa in clearance of an acute P. aeruginosa respiratory infection in rats. Rats were immunized with paraformaldehyde-killed P. aeruginosa at various doses, and 2 weeks later, the rats were challenged with a log10 dose of 8.7 live bacteria. This dose was fatal for unimmunized rats, with death occurring approximately 12 h after challenge. The numbers of surviving bacteria in the airways and lung tissue were determined by analyses of bronchoalveolar lavage fluid (BAL) and lung homogenate samples, respectively. Enhanced bacterial clearance was associated with survival of intra-Peyer's patch-immunized rats. Determination of bacterial clearance in BAL 4 h after challenge demonstrated that the use of all immunization routes led to significant clearance compared with the bacterial levels in unimmunized controls (the order of effectiveness was intra-Peyer's patch > oral-intratracheal > intratracheal > subcutaneous > oral). Bacterial clearance in the lung homogenate was also significantly greater for all immunization routes than in the unimmunized controls (the order of effectiveness was intra-Peyer's patch > subcutaneous > oral-intratracheal > oral = intratracheal). Prior oral immunization with killed P. aeruginosa also induced enhanced bacterial clearance of heterologous strains of P. aeruginosa, Haemophilus influenzae, and to a lesser extent, Klebsiella pneumoniae. Because of the ease of antigen delivery, oral immunization with killed P. aeruginosa may be an important route of immunization for induction of enhanced bacterial clearance of subsequent acute respiratory infection with P. aeruginosa and other gram-negative bacteria.

Full text

PDF
1427

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brett M. M., Ghoneim A. T., Littlewood J. M. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child. 1986 Nov;61(11):1114–1120. doi: 10.1136/adc.61.11.1114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Buret A., Dunkley M., Clancy R. L., Cripps A. W. Effector mechanisms of intestinally induced immunity to Pseudomonas aeruginosa in the rat lung: role of neutrophils and leukotriene B4. Infect Immun. 1993 Feb;61(2):671–679. doi: 10.1128/iai.61.2.671-679.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cash H. A., Woods D. E., McCullough B., Johanson W. G., Jr, Bass J. A. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis. 1979 Mar;119(3):453–459. doi: 10.1164/arrd.1979.119.3.453. [DOI] [PubMed] [Google Scholar]
  4. Cryz S. J., Jr, Fürer E., Germanier R. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun. 1984 Mar;43(3):795–799. doi: 10.1128/iai.43.3.795-799.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cryz S. J., Jr, Lang A. B., Sadoff J. C., Germanier R., Fürer E. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect Immun. 1987 Jul;55(7):1547–1551. doi: 10.1128/iai.55.7.1547-1551.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cryz S. J., Jr, Sadoff J. C., Ohman D., Fürer E. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. J Lab Clin Med. 1988 Jun;111(6):701–707. [PubMed] [Google Scholar]
  7. Dunkley M. L., Husband A. J. Distribution and functional characteristics of antigen-specific helper T cells arising after Peyer's patch immunization. Immunology. 1987 Aug;61(4):475–482. [PMC free article] [PubMed] [Google Scholar]
  8. Dunkley M. L., Husband A. J. Routes of priming and challenge for IgA antibody-containing cell responses in the intestine. Immunol Lett. 1990 Nov;26(2):165–170. doi: 10.1016/0165-2478(90)90140-l. [DOI] [PubMed] [Google Scholar]
  9. Dunkley M. L., Husband A. J. The induction and migration of antigen-specific helper cells for IgA responses in the intestine. Immunology. 1986 Mar;57(3):379–385. [PMC free article] [PubMed] [Google Scholar]
  10. Döring G., Høiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun. 1983 Oct;42(1):197–201. doi: 10.1128/iai.42.1.197-201.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Finke M., Duchêne M., Eckhardt A., Domdey H., von Specht B. U. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infect Immun. 1990 Jul;58(7):2241–2244. doi: 10.1128/iai.58.7.2241-2244.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Finke M., Muth G., Reichhelm T., Thoma M., Duchêne M., Hungerer K. D., Domdey H., von Specht B. U. Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies. Infect Immun. 1991 Apr;59(4):1251–1254. doi: 10.1128/iai.59.4.1251-1254.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Freihorst J., Merrick J. M., Ogra P. L. Effect of oral immunization with Pseudomonas aeruginosa on the development of specific antibacterial immunity in the lungs. Infect Immun. 1989 Jan;57(1):235–238. doi: 10.1128/iai.57.1.235-238.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gilleland H. E., Jr, Gilleland L. B., Matthews-Greer J. M. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect Immun. 1988 May;56(5):1017–1022. doi: 10.1128/iai.56.5.1017-1022.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gilleland H. E., Jr, Parker M. G., Matthews J. M., Berg R. D. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice. Infect Immun. 1984 Apr;44(1):49–54. doi: 10.1128/iai.44.1.49-54.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hancock R. E., Mutharia L. M., Chan L., Darveau R. P., Speert D. P., Pier G. B. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun. 1983 Oct;42(1):170–177. doi: 10.1128/iai.42.1.170-177.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hansen E. J., Hart D. A., McGehee J. L., Toews G. B. Immune enhancement of pulmonary clearance of nontypable Haemophilus influenzae. Infect Immun. 1988 Jan;56(1):182–190. doi: 10.1128/iai.56.1.182-190.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Henry R. L., Mellis C. M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992 Mar;12(3):158–161. doi: 10.1002/ppul.1950120306. [DOI] [PubMed] [Google Scholar]
  19. Husband A. J. Mucosal immune interactions in intestine, respiratory tract and mammary gland. Prog Vet Microbiol Immunol. 1985;1:25–57. [PubMed] [Google Scholar]
  20. Jackson A. E., Southern P. M., Pierce A. K., Fallis B. D., Sanford J. P. Pulmonary clearance of gram-negative bacilli. J Lab Clin Med. 1967 May;69(5):833–841. [PubMed] [Google Scholar]
  21. Klinger J. D., Cash H. A., Wood R. E., Miler J. J. Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats. Infect Immun. 1983 Mar;39(3):1377–1384. doi: 10.1128/iai.39.3.1377-1384.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Langford D. T., Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. Arch Dis Child. 1984 Dec;59(12):1131–1134. doi: 10.1136/adc.59.12.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McDermott M. R., Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol. 1979 May;122(5):1892–1898. [PubMed] [Google Scholar]
  24. Pedersen S. S., Espersen F., Høiby N., Jensen T. Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. J Clin Microbiol. 1990 Apr;28(4):747–755. doi: 10.1128/jcm.28.4.747-755.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pennington J. E., Hickey W. F., Blackwood L. L., Arnaut M. A. Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs. J Clin Invest. 1981 Nov;68(5):1140–1148. doi: 10.1172/JCI110358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pier G. B., Markham R. B. Induction in mice of cell-mediated immunity to Pseudomonas aeruginosa by high molecular weight polysaccharide and vinblastine. J Immunol. 1982 May;128(5):2121–2125. [PubMed] [Google Scholar]
  27. Pier G. B., Small G. J., Warren H. B. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science. 1990 Aug 3;249(4968):537–540. doi: 10.1126/science.2116663. [DOI] [PubMed] [Google Scholar]
  28. Pier G. B., Thomas D., Small G., Siadak A., Zweerink H. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide. Infect Immun. 1989 Jan;57(1):174–179. doi: 10.1128/iai.57.1.174-179.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rosok M. J., Stebbins M. R., Connelly K., Lostrom M. E., Siadak A. W. Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa. Infect Immun. 1990 Dec;58(12):3819–3828. doi: 10.1128/iai.58.12.3819-3828.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sawada S., Suzuki M., Kawamura T., Fujinaga S., Masuho Y., Tomibe K. Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. J Infect Dis. 1984 Oct;150(4):570–576. doi: 10.1093/infdis/150.4.570. [DOI] [PubMed] [Google Scholar]
  31. Schaad U. B., Lang A. B., Wedgwood J., Ruedeberg A., Que J. U., Fürer E., Cryz S. J., Jr Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet. 1991 Nov 16;338(8777):1236–1237. doi: 10.1016/0140-6736(91)92103-9. [DOI] [PubMed] [Google Scholar]
  32. Schook L. B., Carrick L., Jr, Berk R. S. Experimental pulmonary infection of mice by tracheal intubation of Pseudomonas aeruginosa: the use of antineoplastic agents to overcome natural resistance. Can J Microbiol. 1977 Jun;23(6):823–826. doi: 10.1139/m77-120. [DOI] [PubMed] [Google Scholar]
  33. Sordelli D. O., Cerquetti M. C., Hooke A. M., Bellanti J. A. Enhancement of Pseudomonas aeruginosa lung clearance after local immunization with a temperature-sensitive mutant. Infect Immun. 1983 Mar;39(3):1275–1279. doi: 10.1128/iai.39.3.1275-1279.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sordelli D. O., Cerquetti M. C., Hooke A. M. Replication rate of Pseudomonas aeruginosa in the murine lung. Infect Immun. 1985 Nov;50(2):388–391. doi: 10.1128/iai.50.2.388-391.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sorensen R. U., Stern R. C., Polmar S. H. Cellular immunity to bacteria: impairment of in vitro lymphocyte responses to Pseudomonas aeruginosa in cystic fibrosis patients. Infect Immun. 1977 Dec;18(3):735–740. doi: 10.1128/iai.18.3.735-740.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Terashima M., Uezumi I., Tomio T., Kato M., Irie K., Okuda T., Yokota S., Noguchi H. A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide. Infect Immun. 1991 Jan;59(1):1–6. doi: 10.1128/iai.59.1.1-6.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Toews G. B., Gross G. N., Pierce A. K. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis. 1979 Sep;120(3):559–566. doi: 10.1164/arrd.1979.120.3.559. [DOI] [PubMed] [Google Scholar]
  38. Toews G. B., Hart D. A., Hansen E. J. Effect of systemic immunization on pulmonary clearance of Haemophilus influenzae type b. Infect Immun. 1985 May;48(2):343–349. doi: 10.1128/iai.48.2.343-349.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Wallace F. J., Clancy R. L., Cripps A. W. An animal model demonstration of enhanced clearance of nontypable Haemophilus influenzae from the respiratory tract after antigen stimulation of gut-associated lymphoid tissue. Am Rev Respir Dis. 1989 Aug;140(2):311–316. doi: 10.1164/ajrccm/140.2.311. [DOI] [PubMed] [Google Scholar]
  40. Woods D. E., Bryan L. E. Studies on the ability of alginate to act as a protective immunogen against infection with Pseudomonas aeruginosa in animals. J Infect Dis. 1985 Apr;151(4):581–588. doi: 10.1093/infdis/151.4.581. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES